$26.17
+0.03 (+0.11%)
Last updated: May 31, 2026 05:38
Fundamentals Overview
Pfizer Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Intrinsic value (DCF)
+53.5% upside vs price
Profitability
Risk (Beta)
0.31 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +53.5% upside vs price · Analyst grade: B+
Pressures (Sell):
3M vs S&P 500: -12.5%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: mixed. Current institutional positions: Buy: 9, Equal Weight: 5, Neutral: 15, Underperform: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $40.18; current price is $26.17. That’s a +53.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 20.02 |
| DCF value (model) | $40.18 (53.5% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 1.65 |
| P/S (TTM) | 2.36 |
| P/FCF (TTM) | 15.73 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.25 |
| Quick Ratio (TTM) | 0.94 |
| Cash Ratio (TTM) | 0.05 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 11.83% |
| Gross margin (TTM) | 69.35% |
| Operating margin (TTM) | 23.45% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for PFE.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Citigroup | maintain | Neutral | Neutral | 2026-04-29 |
| RBC Capital | maintain | Underperform | Underperform | 2026-04-20 |
| UBS | maintain | Neutral | Neutral | 2026-04-13 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-04-10 |
| B of A Securities | maintain | Neutral | Neutral | 2026-04-09 |
| Guggenheim | maintain | Buy | Buy | 2026-03-24 |
| HSBC | maintain | Buy | Buy | 2026-03-17 |
| Argus Research | upgrade | Hold | Buy | 2026-03-02 |
| Freedom Broker | maintain | Buy | Buy | 2026-02-09 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2026-02-04 |
| Cantor Fitzgerald | maintain | Neutral | Neutral | 2026-01-27 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-12-17 |
| B of A Securities | maintain | Neutral | Neutral | 2025-12-15 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-12-12 |
| Guggenheim | maintain | Buy | Buy | 2025-11-24 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-10-10 |
| B of A Securities | maintain | Neutral | Neutral | 2025-10-03 |
| Citigroup | maintain | Neutral | Neutral | 2025-08-06 |
| B of A Securities | maintain | Neutral | Neutral | 2025-08-06 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-08-06 |
| UBS | maintain | Neutral | Neutral | 2025-04-30 |
| Goldman Sachs | downgrade | Buy | Neutral | 2025-04-08 |
| UBS | maintain | Neutral | Neutral | 2025-04-08 |
| Guggenheim | maintain | Buy | Buy | 2025-03-18 |
| Guggenheim | maintain | Buy | Buy | 2025-03-12 |
| Guggenheim | maintain | Buy | Buy | 2025-02-10 |
| UBS | maintain | Neutral | Neutral | 2025-02-05 |
| Citigroup | maintain | Neutral | Neutral | 2025-01-28 |
| UBS | maintain | Neutral | Neutral | 2025-01-08 |
| Truist Securities | maintain | Buy | Buy | 2024-12-18 |